Ferryx develops next generation probiotics to improve gut health for those experiencing an active flare-up of a gut condition
Ferryx Ltd was formed in 2019 as a spin-out from the University of Bristol to take next generation probiotics into commercial production. It is built on the back of 10 years' research and development at the University of Bristol.
Meet the people behind Ferryx
Dr Jenny Bailey Cooper
Chief Executive Officer
Dr Jenny Bailey Cooper has spent her career to date working in the field of gut health. She has a PhD in gastrointestinal immunology and 18 years’ research experience in gastrointestinal disease. Jenny has a keen interest in intestinal inflammation, particularly mucosal barrier function and novel therapeutics to disrupt inflammatory pathways. In 2019 Jenny became Co-founder and Chief Executive Officer of Ferryx. She has been responsible for the development of Ferryx's proprietary products since their early stages and has led commercialisation over the last four years. Jenny has led Ferryx through investment rounds, successful grant funding, and into revenue generation via launch of Ferryx's first product, Ferrocalm, in December 2022
Dr Tristan Cogan
Chief Technical Officer
Dr Tristan Cogan is Co-founder of Ferryx Ltd and a Senior Lecturer in Infectious Disease at the University of Bristol’s Veterinary School. He has worked on gastrointestinal disease for 20 years, first for the Health Protection Agency and more recently at the University of Bristol. His research expertise is in the dynamics of bacterial populations during disease and their interaction with the host. He has obtained and supervised at either PI or Co-I level over £4.5 M of grant funding in this area. He works with a number of companies across Europe and North America advising on and carrying out the development of novel antimicrobial agents in animal health indications. He has expertise in bacterial physiology and growth and how culture can be scaled up from the lab to industrial capacity, areas on which he has advised the Kuwaiti government. His interests lie in the development of novel or disruptive technologies and progressing these from idea to proven treatment.
Dr John Fox
Chair of the Board and Development Advisor
Dr John Fox has over 30 years’ experience of drug development, due diligence and licensing in multinational and early biotech companies. After obtaining his PhD from Queens University Belfast and spending some years in the Dept. of Therapeutics and Pharmacology, he joined the pharmaceutical industry with Eli Lilly. Subsequently he managed translational development projects at Shire Pharmaceuticals and was appointed Group Director of Planning before co-founding Hunter Fleming to license and develop university technologies in the field of neuroprotection. As Chief Operations Officer he was instrumental in licensing, funding and developing a number of projects from bench research to clinical development. After Hunter Fleming’s portfolio was acquired by Newron SpA, Dr Fox served as Chief Development Officer and subsequently Chief Executive of Merrion Pharmaceuticals plc, a drug delivery company based in Dublin, before returning to the UK.
He is currently Chief Executive of a London-based university spin-out, a non-executive director of a drug delivery spin-out from Queens University Belfast, and has supported entrepreneurs as a mentor through the Duke of York’s initiative Pitch at the Palace and ICURe. He has been involved in commercial feasibility assessment of university research in both Ireland and the UK, and has served as a non-executive director of Southampton Innovations.
FERRYX LTD
Future Space,
UWE North Gate,
Filton Road,
Bristol,
BS34 8RB.
Follow Us
